Llerena, SusanaCabezas, JoaquínCuadrado, AntonioManuel Olmos, JoséGonzález, MartaGarcía, FedericoCobo, CarmenCrespo, Javier2023-01-252023-01-2520191665-2681http://hdl.handle.net/10668/13999Nowadays, the retreatment of patients with Hepatitis C virus (HCV) genotype 3 (GT3) especially cirrhotic, who have already been treated with regimens containing a NS5A inhibitor represents a challenge. Use a novel retreatment option for patients with a difficult approach. We present three case reports of retreatment with a new combination of Direct-acting antivirals (DAAs), Sofosbuvir, Elbasvir/Grazoprevir in patients with GT3 with a previous failure with Sofosbuvir/Ledipasvir. All the cases achieved sustained virologic response (SVR) at week +12 without adverse effects. In our experience, this combo may represent an effective and safe option for these patients.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Genotype 3Grazoprevir + ElbasvirHepatitis C virusSofosbuvirTreatment failureAmidesAntiviral AgentsBenzofuransCarbamatesCyclopropanesDrug Resistance, ViralDrug Therapy, CombinationGenotypeHepacivirusHepatitis C, ChronicHumansImidazolesMaleMiddle AgedQuinoxalinesRNA, ViralRetreatmentSofosbuvirSulfonamidesTreatment Failureresearch article31113598open access10.5604/01.3001.0012.7931https://doi.org/10.5604/01.3001.0012.7931